US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

DOGWOOD THERAPEUTICS INC

1.46

+0.03002.10%

Post-market: 1.540.0830+5.68%19:24 EDT

Volume:71.09K

Turnover:105.99K

Market Cap:49.63M

PE:-0.16

High:1.56

Open:1.45

Low:1.43

Close:1.43

52wk High:7.30

52wk Low:1.28

Shares:33.99M

Float Shares:5.81M

Volume Ratio:1.32

T/O Rate:1.22%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-8.9478

EPS(LYR):-7.1350

ROE:-47.77%

ROA:-20.83%

PB:0.73

PE(LYR):-0.20

Loading ...

Overview Company News Filings

Dogwood Therapeutics Posts Corporate Presentation on Non-opioid Pain, Neuropathy Drug Pipeline

Dogwood Therapeutics Names Orbimed’s Iain Dukes Chair of New Scientific Advisory Board

Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at Orbimed, as Chair of Scientific Advisory Board

THOMSON REUTERS

Dogwood Therapeutics shareholders approve charter amendment increasing authorized shares

Dogwood Therapeutics posts corporate presentation on non-opioid pain, neuropathy drug pipeline

Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), MoonLake Immunotherapeutics (MLTX) and Dogwood Therapeutics (DWTX)

Dogwood Therapeutics launches 12-week Halneuron Phase 2b CINP extension trial

Dogwood Therapeutics Inc - Top-Line Results From Double-Blinded Cinp Study Expected in Fall 2026

THOMSON REUTERS

Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2B Long Term Extension Study

THOMSON REUTERS

Dogwood Therapeutics Inc - Extension Trial Data to Support FDA Submission for Phase 3 Program in H1 2027

THOMSON REUTERS

Dogwood Therapeutics Q1 net loss narrows to $5 million

Dogwood Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Dogwood Therapeutics Q1 net loss narrows, no revenue reported

Dogwood Therapeutics Inc - Announces Partnership for Legacy Antiviral Assets With Potential Value up to $100 Mln

THOMSON REUTERS

Dogwood Therapeutics Inc - Q1 2026 Net Loss Attributable to Common Stockholders Was $5.0 Mln or $0.15 per Share

THOMSON REUTERS

Dogwood Therapeutics Announces First Quarter 2026 Financial Results

THOMSON REUTERS

Dogwood Therapeutics Q1 Net Income USD -5 Million

THOMSON REUTERS

Dogwood Therapeutics posts corporate presentation on non-opioid pain, neuropathy drug pipeline

Dogwood Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview

Dogwood Therapeutics to report Q1 2026 financial results before market open

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/DWTX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DWTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DWTX\",,,,,undefined,":{"symbol":"DWTX","market":"US","secType":"STK","nameCN":"DOGWOOD THERAPEUTICS INC","latestPrice":1.46,"timestamp":1790971200000,"preClose":1.43,"halted":0,"volume":71089,"hourTrading":{"tag":"盘后","latestPrice":1.543,"preClose":1.46,"latestTime":"19:24 EDT","volume":174,"amount":267.021,"timestamp":1790983481762,"change":0.083,"changeRate":0.056849,"amplitude":0.056849},"delay":0,"changeRate":0.020979020979020997,"floatShares":5809900,"shares":33992600,"eps":-8.9478,"marketStatus":"Closed","change":0.03,"latestTime":"10-02 16:00:00 EDT","open":1.45,"high":1.5599,"low":1.43,"amount":105986.39815970001,"amplitude":0.090839,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-8.9478,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":5,"adr":0,"listingDate":1608181200000,"exchange":"NASDAQ","adjPreClose":1.43,"preHourTrading":{"tag":"盘前","latestPrice":1.45,"preClose":1.43,"latestTime":"07:54 EDT","volume":77,"amount":110.9672025,"timestamp":1790942061934,"change":0.02,"changeRate":0.013986,"amplitude":0.020979},"postHourTrading":{"tag":"盘后","latestPrice":1.543,"preClose":1.46,"latestTime":"19:24 EDT","volume":174,"amount":267.021,"timestamp":1790983481762,"change":0.083,"changeRate":0.056849,"amplitude":0.056849},"volumeRatio":1.321652},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DWTX\",,,,,undefined,":{"symbol":"DWTX","floatShares":5809900,"roa":"-20.83%","roe":"-47.77%","lyrEps":-7.13499,"volumeRatio":1.321652,"shares":33992600,"dividePrice":0,"high":1.5599,"amplitude":0.090839,"preClose":1.43,"low":1.43,"week52Low":1.28,"pbRate":"0.73","week52High":7.3,"institutionHeld":0,"latestPrice":1.46,"eps":-8.9478,"divideRate":0,"volume":71089,"delay":0,"ttmEps":-8.9478,"open":1.45,"prevYearClose":4.16,"prevWeekClose":1.36,"prevMonthClose":1.35,"prevQuarterClose":1.35,"fiveDayClose":1.36,"twentyDayClose":2.36,"sixtyDayClose":1.41},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DWTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"DWTX","fiscalQuarterEnding":"2026/06","expectedEps":-0.13,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"pre","actualEps":-0.34},{"market":"US","date":"2026-05-14","symbol":"DWTX","fiscalQuarterEnding":"2026/03","expectedEps":-0.22,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778731200000,"reportTimeType":"pre","actualEps":-0.15},{"market":"US","date":"2026-03-18","symbol":"DWTX","fiscalQuarterEnding":"2025/12","expectedEps":-1.22,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1773806400000,"reportTimeType":"pre","actualEps":-0.26},{"market":"US","date":"2025-11-06","symbol":"DWTX","fiscalQuarterEnding":"2025/09","expectedEps":-1.23,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"pre","actualEps":-8.2},{"market":"US","date":"2025-08-13","symbol":"DWTX","fiscalQuarterEnding":"2025/06","expectedEps":-1.26,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"pre","actualEps":-1.99}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DWTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DWTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1745467200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/DWTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"DWTX","date":"2026-10-01","current":-0.170992,"percent":0.46748,"low":-5.30677,"twenty":-2.186892,"median":-1.124597,"eighty":-0.423897,"high":-0.31572,"avg":-1.341888,"sd":0.986672,"marketCap":45889946},"quantilePoints":[{"date":"2024-10-11","current":-0.88829,"twenty":-0.871777,"median":-0.847007,"eighty":-0.822237,"marketCap":4156676},{"date":"2024-10-18","current":-1.14168,"twenty":-1.243599,"median":-1.14168,"eighty":-0.919038,"marketCap":5342394},{"date":"2024-10-25","current":-1.352393,"twenty":-1.244175,"median":-1.155915,"eighty":-1.05342,"marketCap":6328406},{"date":"2024-10-31","current":-1.184386,"twenty":-1.27834,"median":-1.174407,"eighty":-1.098974,"marketCap":5542234},{"date":"2024-11-08","current":-1.035557,"twenty":-1.27834,"median":-1.184386,"eighty":-1.098974,"marketCap":5928592},{"date":"2024-11-15","current":-0.74467,"twenty":-1.269799,"median":-1.17156,"eighty":-0.88829,"marketCap":4263257},{"date":"2024-11-22","current":-0.6306,"twenty":-1.266952,"median":-1.124597,"eighty":-0.74467,"marketCap":3610202},{"date":"2024-11-29","current":-0.558465,"twenty":-1.264674,"median":-1.042032,"eighty":-0.629204,"marketCap":3197227},{"date":"2024-12-06","current":-0.532869,"twenty":-1.261826,"median":-0.94447,"eighty":-0.591959,"marketCap":3050687},{"date":"2024-12-13","current":-0.560792,"twenty":-1.247591,"median":-0.805175,"eighty":-0.586099,"marketCap":3210548},{"date":"2024-12-20","current":-0.53985,"twenty":-1.196344,"median":-0.717909,"eighty":-0.564981,"marketCap":3090652},{"date":"2024-12-27","current":-0.609658,"twenty":-1.179261,"median":-0.679489,"eighty":-0.564515,"marketCap":3490306},{"date":"2025-01-03","current":-0.584061,"twenty":-1.174695,"median":-0.665504,"eighty":-0.565461,"marketCap":3343766},{"date":"2025-01-10","current":-0.553811,"twenty":-1.172405,"median":-0.646888,"eighty":-0.565454,"marketCap":3170583},{"date":"2025-01-17","current":-0.449099,"twenty":-1.164457,"median":-0.623619,"eighty":-0.558465,"marketCap":2571103},{"date":"2025-01-24","current":-3.106463,"twenty":-1.170151,"median":-0.6306,"eighty":-0.558465,"marketCap":17784576},{"date":"2025-01-31","current":-2.969173,"twenty":-1.244175,"median":-0.653869,"eighty":-0.558465,"marketCap":16998591},{"date":"2025-02-07","current":-2.748114,"twenty":-1.269799,"median":-0.667831,"eighty":-0.560792,"marketCap":15733022},{"date":"2025-02-14","current":-1.561376,"twenty":-1.386529,"median":-0.691147,"eighty":-0.563119,"marketCap":8938914},{"date":"2025-02-21","current":-1.36824,"twenty":-1.406654,"median":-0.738827,"eighty":-0.564981,"marketCap":7833206},{"date":"2025-02-28","current":-1.095988,"twenty":-1.389852,"median":-0.805175,"eighty":-0.565476,"marketCap":6274558},{"date":"2025-03-07","current":-1.030834,"twenty":-1.384928,"median":-0.926984,"eighty":-0.569177,"marketCap":5901548},{"date":"2025-03-14","current":-1.798723,"twenty":-1.448286,"median":-1.000651,"eighty":-0.577546,"marketCap":10297735},{"date":"2025-03-21","current":-1.056947,"twenty":-1.431015,"median":-0.999453,"eighty":-0.58313,"marketCap":13053004},{"date":"2025-03-28","current":-0.925409,"twenty":-1.421838,"median":-0.979572,"eighty":-0.584992,"marketCap":11428545},{"date":"2025-04-04","current":-0.646858,"twenty":-1.406654,"median":-0.930825,"eighty":-0.586099,"marketCap":7988515},{"date":"2025-04-11","current":-0.317141,"twenty":-1.389852,"median":-0.88829,"eighty":-0.58313,"marketCap":3916603},{"date":"2025-04-17","current":-0.402359,"twenty":-1.385328,"median":-0.805724,"eighty":-0.565469,"marketCap":4969023},{"date":"2025-04-25","current":-0.61055,"twenty":-1.374755,"median":-0.785584,"eighty":-0.565469,"marketCap":7540127},{"date":"2025-05-02","current":-0.578189,"twenty":-1.358732,"median":-0.74467,"eighty":-0.568254,"marketCap":7140474},{"date":"2025-05-09","current":-0.374989,"twenty":-1.330168,"median":-0.724741,"eighty":-0.565469,"marketCap":8714743},{"date":"2025-05-16","current":-0.451467,"twenty":-1.293145,"median":-0.691147,"eighty":-0.558465,"marketCap":10492092},{"date":"2025-05-23","current":-0.435842,"twenty":-1.273215,"median":-0.667831,"eighty":-0.549157,"marketCap":10128978},{"date":"2025-05-30","current":-0.43502,"twenty":-1.26866,"median":-0.661674,"eighty":-0.542709,"marketCap":10109867},{"date":"2025-06-06","current":-0.424679,"twenty":-1.265813,"median":-0.656935,"eighty":-0.524492,"marketCap":9335860},{"date":"2025-06-13","current":-0.450325,"twenty":-1.262965,"median":-0.649201,"eighty":-0.469065,"marketCap":9899643},{"date":"2025-06-20","current":-0.417289,"twenty":-1.258453,"median":-0.635392,"eighty":-0.460532,"marketCap":9173414},{"date":"2025-06-27","current":-0.414681,"twenty":-1.246626,"median":-0.62674,"eighty":-0.450325,"marketCap":9116080},{"date":"2025-07-03","current":-0.417289,"twenty":-1.244175,"median":-0.623619,"eighty":-0.448744,"marketCap":9173414},{"date":"2025-07-11","current":-0.433807,"twenty":-1.191392,"median":-0.616057,"eighty":-0.435137,"marketCap":9536528},{"date":"2025-07-18","current":-0.413812,"twenty":-1.184386,"median":-0.61055,"eighty":-0.430908,"marketCap":9096969},{"date":"2025-07-25","current":-0.411204,"twenty":-1.175845,"median":-0.606188,"eighty":-0.428591,"marketCap":9039635},{"date":"2025-08-01","current":-0.420332,"twenty":-1.175104,"median":-0.602999,"eighty":-0.424679,"marketCap":9240303},{"date":"2025-08-08","current":-0.425287,"twenty":-1.172969,"median":-0.594948,"eighty":-0.422505,"marketCap":9349238},{"date":"2025-08-15","current":-0.380049,"twenty":-1.170151,"median":-0.588976,"eighty":-0.421636,"marketCap":9402749},{"date":"2025-08-22","current":-0.381594,"twenty":-1.165796,"median":-0.584643,"eighty":-0.419028,"marketCap":9440972},{"date":"2025-08-29","current":-0.370394,"twenty":-1.14168,"median":-0.579408,"eighty":-0.417298,"marketCap":9163858},{"date":"2025-09-05","current":-0.386229,"twenty":-1.128014,"median":-0.578189,"eighty":-0.417289,"marketCap":9555640},{"date":"2025-09-12","current":-0.378257,"twenty":-1.116602,"median":-0.565465,"eighty":-0.414688,"marketCap":9358411},{"date":"2025-09-19","current":-0.371892,"twenty":-1.1021,"median":-0.560792,"eighty":-0.413812,"marketCap":9200934},{"date":"2025-09-26","current":-0.394726,"twenty":-1.096585,"median":-0.556138,"eighty":-0.410856,"marketCap":9765864},{"date":"2025-10-03","current":-0.495918,"twenty":-1.064755,"median":-0.553811,"eighty":-0.413012,"marketCap":12269441},{"date":"2025-10-10","current":-0.519049,"twenty":-1.045015,"median":-0.552647,"eighty":-0.413742,"marketCap":12841707},{"date":"2025-10-17","current":-0.55705,"twenty":-1.036852,"median":-0.55705,"eighty":-0.413812,"marketCap":13781903},{"date":"2025-10-24","current":-0.520902,"twenty":-1.035502,"median":-0.552647,"eighty":-0.413812,"marketCap":12887570},{"date":"2025-10-31","current":-0.61637,"twenty":-1.031765,"median":-0.55705,"eighty":-0.414507,"marketCap":15249527},{"date":"2025-11-07","current":-0.481974,"twenty":-1.007156,"median":-0.555431,"eighty":-0.414681,"marketCap":11924442},{"date":"2025-11-14","current":-0.327725,"twenty":-1.000768,"median":-0.549157,"eighty":-0.413742,"marketCap":12520664},{"date":"2025-11-21","current":-0.357136,"twenty":-0.998735,"median":-0.545565,"eighty":-0.409242,"marketCap":13644313},{"date":"2025-11-28","current":-0.391355,"twenty":-0.987046,"median":-0.544503,"eighty":-0.403493,"marketCap":14951645},{"date":"2025-12-05","current":-0.368541,"twenty":-0.971236,"median":-0.53985,"eighty":-0.398837,"marketCap":14080014},{"date":"2025-12-12","current":-4.995522,"twenty":-0.987046,"median":-0.53985,"eighty":-0.39658,"marketCap":190852899},{"date":"2025-12-19","current":-4.746524,"twenty":-1.032696,"median":-0.544503,"eighty":-0.398429,"marketCap":181339982},{"date":"2025-12-26","current":-3.40816,"twenty":-1.050981,"median":-0.545001,"eighty":-0.398837,"marketCap":130208053},{"date":"2026-01-02","current":-3.236974,"twenty":-1.111477,"median":-0.549157,"eighty":-0.39905,"marketCap":123667922},{"date":"2026-01-09","current":-2.451074,"twenty":-1.16928,"median":-0.552647,"eighty":-0.399948,"marketCap":93642777},{"date":"2026-01-16","current":-2.351299,"twenty":-1.182678,"median":-0.557977,"eighty":-0.400578,"marketCap":89830899},{"date":"2026-01-23","current":-2.578032,"twenty":-1.247239,"median":-0.558465,"eighty":-0.402359,"marketCap":98493164},{"date":"2026-01-30","current":-2.435274,"twenty":-1.269799,"median":-0.561956,"eighty":-0.404249,"marketCap":93039145},{"date":"2026-02-06","current":-2.662007,"twenty":-1.36824,"median":-0.565484,"eighty":-0.407726,"marketCap":101701410},{"date":"2026-02-13","current":-2.536044,"twenty":-1.420694,"median":-0.572344,"eighty":-0.408596,"marketCap":96889041},{"date":"2026-02-20","current":-2.536071,"twenty":-1.540898,"median":-0.574661,"eighty":-0.409242,"marketCap":96890059},{"date":"2026-02-27","current":-2.405345,"twenty":-1.831766,"median":-0.578189,"eighty":-0.409453,"marketCap":91895726},{"date":"2026-03-06","current":-2.492496,"twenty":-2.234293,"median":-0.579338,"eighty":-0.410856,"marketCap":95225281},{"date":"2026-03-13","current":-2.623221,"twenty":-2.344581,"median":-0.583582,"eighty":-0.413012,"marketCap":100219614},{"date":"2026-03-20","current":-2.638773,"twenty":-2.411331,"median":-0.585772,"eighty":-0.413742,"marketCap":90397426},{"date":"2026-03-27","current":-2.028037,"twenty":-2.43626,"median":-0.591133,"eighty":-0.413812,"marketCap":69475230},{"date":"2026-04-02","current":-2.076788,"twenty":-2.435274,"median":-0.593369,"eighty":-0.413812,"marketCap":71145307},{"date":"2026-04-10","current":-1.930536,"twenty":-2.417317,"median":-0.597275,"eighty":-0.414333,"marketCap":66135074},{"date":"2026-04-17","current":-1.521028,"twenty":-2.400116,"median":-0.605004,"eighty":-0.414681,"marketCap":52106422},{"date":"2026-04-24","current":-1.365025,"twenty":-2.394624,"median":-0.608494,"eighty":-0.414681,"marketCap":46762174},{"date":"2026-05-01","current":-1.394276,"twenty":-2.368094,"median":-0.611014,"eighty":-0.414686,"marketCap":47764220},{"date":"2026-05-08","current":-1.521028,"twenty":-2.346261,"median":-0.615922,"eighty":-0.415207,"marketCap":52106422},{"date":"2026-05-15","current":-1.930536,"twenty":-2.342443,"median":-0.621292,"eighty":-0.416072,"marketCap":66135074},{"date":"2026-05-22","current":-2.134847,"twenty":-2.337557,"median":-0.626653,"eighty":-0.416941,"marketCap":60456810},{"date":"2026-05-29","current":-1.969721,"twenty":-2.321068,"median":-0.62867,"eighty":-0.417289,"marketCap":55780593},{"date":"2026-06-05","current":-1.981516,"twenty":-2.281465,"median":-0.637581,"eighty":-0.417289,"marketCap":56114609},{"date":"2026-06-12","current":-1.851774,"twenty":-2.23843,"median":-0.653869,"eighty":-0.417289,"marketCap":52440438},{"date":"2026-06-18","current":-1.757416,"twenty":-2.210516,"median":-0.657312,"eighty":-0.417291,"marketCap":49768313},{"date":"2026-06-26","current":-1.757537,"twenty":-2.179667,"median":-0.663177,"eighty":-0.41747,"marketCap":49771738},{"date":"2026-07-02","current":-1.781287,"twenty":-2.170232,"median":-0.667831,"eighty":-0.418159,"marketCap":50444329},{"date":"2026-07-10","current":-1.67441,"twenty":-2.158437,"median":-0.69531,"eighty":-0.419028,"marketCap":47417669},{"date":"2026-07-17","current":-1.626909,"twenty":-2.134847,"median":-0.732985,"eighty":-0.419028,"marketCap":46072487},{"date":"2026-07-24","current":-1.828788,"twenty":-2.113794,"median":-0.753635,"eighty":-0.419028,"marketCap":51789511},{"date":"2026-07-31","current":-1.876289,"twenty":-2.111765,"median":-0.785584,"eighty":-0.419723,"marketCap":53134693},{"date":"2026-08-07","current":-2.078168,"twenty":-2.116169,"median":-0.805724,"eighty":-0.420245,"marketCap":58851717},{"date":"2026-08-14","current":-2.351299,"twenty":-2.160796,"median":-0.905302,"eighty":-0.42068,"marketCap":66586514},{"date":"2026-08-21","current":-2.197553,"twenty":-2.17317,"median":-0.936241,"eighty":-0.421462,"marketCap":79202648},{"date":"2026-08-28","current":-2.188122,"twenty":-2.185661,"median":-0.988914,"eighty":-0.421636,"marketCap":78862722},{"date":"2026-09-04","current":-2.225848,"twenty":-2.231137,"median":-1.001237,"eighty":-0.421636,"marketCap":80222425},{"date":"2026-09-11","current":-1.773133,"twenty":-2.220922,"median":-1.035488,"eighty":-0.422157,"marketCap":63905999},{"date":"2026-09-18","current":-1.622228,"twenty":-2.205587,"median":-1.049489,"eighty":-0.422766,"marketCap":58467191},{"date":"2026-09-25","current":-1.348713,"twenty":-2.191894,"median":-1.098974,"eighty":-0.423201,"marketCap":48609350},{"date":"2026-10-01","current":-1.27326,"twenty":-2.186892,"median":-1.124597,"eighty":-0.423897,"marketCap":45889946}],"updateTime":1790952263434},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DWTX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2648659568","title":"Dogwood Therapeutics Posts Corporate Presentation on Non-opioid Pain, Neuropathy Drug Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2648659568","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648659568?lang=en_us&edition=fundamental","pubTime":"2026-07-01 08:37","pubTimestamp":1782866272,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics posts corporate presentation on non-opioid pain, neuropathy drug pipelineDogwood outlined key 2026 milestones for Halneuron injection in chemotherapy-induced neuropathic pain, inc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDLbKDWXj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647955691","title":"Dogwood Therapeutics Names Orbimed’s Iain Dukes Chair of New Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2647955691","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647955691?lang=en_us&edition=fundamental","pubTime":"2026-06-30 20:45","pubTimestamp":1782823529,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics names OrbiMed’s Iain Dukes chair of new scientific advisory boardDogwood Therapeutics named OrbiMed venture partner Iain Dukes chair of its newly formed Scientific Advisory Board.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL29F1v7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3T34201.USD","BK4139","SG9999014013.SGD","DWTX","LU1400636491.USD","LU2646069778.SGD","LU2468319806.SGD","SGXZ57979304.SGD","LU1302929846.USD","IE00BN0W2T93.GBP","LU0289739699.SGD","LU1481599808.USD","NDAQ","IE00BWDBJ516.SGD","LU0203347892.USD","LU1228905037.USD","LU0203345920.USD","LU1309081286.SGD","SG9999001176.SGD","LU1400636657.SGD","LU0225771236.USD","LU0225284248.USD","SG9999013999.USD","GSK.UK","IE00BKPKM429.USD","LU0058720904.USD","LU0545562505.USD","LU1202635105.USD","LU0575583348.USD","LU2210150020.SGD","LU0985481810.HKD","LU2210149790.SGD","IE00BQJZX424.USD","LU0987226296.USD","SG9999014005.SGD","LU1645745479.HKD","LU1035777561.USD","LU0971552830.HKD","LU0211331839.USD","LU1481600234.SGD","BK4112","IE00B64PRP62.GBP","LU1046248800.SGD","SG9999014039.USD","LU0161305163.EUR","LU1064927863.SGD","SG9999014021.USD","BK4585","LU0109981661.USD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647556600","title":"Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at Orbimed, as Chair of Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2647556600","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647556600?lang=en_us&edition=fundamental","pubTime":"2026-06-30 20:45","pubTimestamp":1782823500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nTUA4FNDR7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DWTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644243157","title":"Dogwood Therapeutics shareholders approve charter amendment increasing authorized shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2644243157","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644243157?lang=en_us&edition=fundamental","pubTime":"2026-06-18 04:56","pubTimestamp":1781729765,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics held its annual shareholder meeting on June 16, 2026.Shareholders backed an amendment to the certificate of incorporation to increase authorized common and preferred shares; the filing took effect June 17, 2026.Shareholders supported holding future advisory votes on executive pay on an annual basis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 17, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL71cthH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642929527","title":"Dogwood Therapeutics posts corporate presentation on non-opioid pain, neuropathy drug pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2642929527","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642929527?lang=en_us&edition=fundamental","pubTime":"2026-06-12 21:43","pubTimestamp":1781271837,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics highlighted Halneuron injection for chemotherapy-induced neuropathic pain, targeting a Phase 2b data readout in fall 2026.Milestones include a Q4 2026 end-of-Phase 2 FDA submission for Halneuron in CINP.Phase 2b interim analysis set a 210-240 patient sample size to maintain 80%-85% power, citing an efficacy signal versus placebo.Pipeline update flagged SP16 IV in CIPPN with an FDA-accepted IND, with Phase 1b enrollment slated to start in Q3 2026.Corporate snapshot showed USD 13.2 million cash as of March 31, 2026 pro forma, with 33,629,553 shares outstanding.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief on June 12, 2026, and","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDL7bB07z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636863485","title":"Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), MoonLake Immunotherapeutics (MLTX) and Dogwood Therapeutics (DWTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636863485","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636863485?lang=en_us&edition=fundamental","pubTime":"2026-05-20 00:50","pubTimestamp":1779209411,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vir Biotechnology (VIR), MoonLake Immunotherapeutics...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vir-biotechnology-vir-moonlake-immunotherapeutics-mltx-and-dogwood-therapeutics-dwtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vir-biotechnology-vir-moonlake-immunotherapeutics-mltx-and-dogwood-therapeutics-dwtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DWTX","BK4588","BK4139","XLV","LU0029874061.USD","BK4585","HCSG","VIR","MLTX","XBI","BK4137","LABU","BK4581","BK4535","BK4568","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636075180","title":"Dogwood Therapeutics launches 12-week Halneuron Phase 2b CINP extension trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2636075180","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636075180?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:45","pubTimestamp":1779108317,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics launched a Phase 2b open-label extension study of Halneuron for chemotherapy-induced neuropathic pain, enrolling patients who complete its ongoing 4-week double-blind trial.Results from the extension study will be presented in the future, with the main 4-week trial still expected to deliver top-line results in fall 2026.The new 12-week follow-on trial aims to show whether pain relief can be sustained with longer treatment while expanding the safety profile, supporting an end-of-Phase 2 FDA package.An interim assessment from the ongoing study has already indicated a favorable treatment effect versus placebo, backing continued development and informing plans for a Phase 3 program targeted to start in the first half of 2027.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDLbjphsL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK4139","IE00BN0W2W23.USD","SG9999014013.SGD","DWTX","NDAQ","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IE00BKPKM429.USD","LU2210150020.SGD","BK4588","LU2210149790.SGD","LU0314104364.USD","BK4112","IE00B64PRP62.GBP","SG9999014039.USD","IE00BGHQF748.EUR","SG9999014021.USD","BK4585","SG9999014005.SGD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636922075","title":"Dogwood Therapeutics Inc - Top-Line Results From Double-Blinded Cinp Study Expected in Fall 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2636922075","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636922075?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:45","pubTimestamp":1779108300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUA1CSV3X:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636759880","title":"Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2B Long Term Extension Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2636759880","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636759880?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:45","pubTimestamp":1779108300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUA1CSV3X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636759060","title":"Dogwood Therapeutics Inc - Extension Trial Data to Support FDA Submission for Phase 3 Program in H1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2636759060","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636759060?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:45","pubTimestamp":1779108300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUA1CSV3X:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DWTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635748087","title":"Dogwood Therapeutics Q1 net loss narrows to $5 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635748087","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635748087?lang=en_us&edition=fundamental","pubTime":"2026-05-15 21:21","pubTimestamp":1778851292,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics posted a Q1 net loss of $5 million, narrowing from a $10.9 million loss a year earlier.Operating expenses rose 14.6% to $5.08 million, led by R&D up 9.6% to $2.67 million.Cash totaled $13.2 million at March 31, 2026, with management expecting it to fund operations into Q4 2026.Halneuron Phase 2b HAL-CINP-203 trial enrollment reached 164 patients, with top-line data expected in fall 2026.SP16 IND for IV dosing was accepted by FDA, with patient recruitment for an NCI-funded Phase 1 evaluation expected to start in first half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL39txnv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635744851","title":"Dogwood Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635744851","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635744851?lang=en_us&edition=fundamental","pubTime":"2026-05-15 00:36","pubTimestamp":1778776613,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryDogwood Therapeutics Inc DWTX.OQ reported a quarterly adjusted loss of 7 cents per share for the quarter ended","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL8N41R213:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635717231","title":"Dogwood Therapeutics Q1 net loss narrows, no revenue reported","url":"https://stock-news.laohu8.com/highlight/detail?id=2635717231","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635717231?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:38","pubTimestamp":1778762318,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Q1 net loss narrows, no revenue reportedOverviewU.S. biopharma developer reported no Q1 revenue, net loss narrowed from prior yearQ1 R&D and G&A expenses rose due to increased dru","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL1N41R0N5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635717973","title":"Dogwood Therapeutics Inc - Announces Partnership for Legacy Antiviral Assets With Potential Value up to $100 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2635717973","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635717973?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:30","pubTimestamp":1778761801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUAPHPR2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DWTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635717134","title":"Dogwood Therapeutics Inc - Q1 2026 Net Loss Attributable to Common Stockholders Was $5.0 Mln or $0.15 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2635717134","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635717134?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:30","pubTimestamp":1778761801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUAPHPR2:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DWTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635176417","title":"Dogwood Therapeutics Announces First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2635176417","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635176417?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:30","pubTimestamp":1778761801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUAPHPR2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635696717","title":"Dogwood Therapeutics Q1 Net Income USD -5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635696717","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635696717?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:30","pubTimestamp":1778761800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nPLX28B062:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DWTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635244377","title":"Dogwood Therapeutics posts corporate presentation on non-opioid pain, neuropathy drug pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2635244377","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635244377?lang=en_us&edition=fundamental","pubTime":"2026-05-13 02:33","pubTimestamp":1778610804,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics outlined pipeline focus on non-opioid pain and neuropathy drugs led by Halneuron injection for chemotherapy-induced neuropathic pain , with Phase 2b data anticipated in 3Q26.Halneuron, a tetrodotoxin-based NaV1.7 sodium channel blocker administered by subcutaneous injection, is being studied in a 4-week Phase 2b trial with final data projected for fall 2026.SP16 IV, which targets LRP1 signaling, has an FDA-accepted IND for chemotherapy-induced peripheral neuropathy, with Phase 1b enrollment expected to start mid-2026.Cash position listed at USD 13.2 million pro forma as of March 31, 2026; shares outstanding 33,629,553.Pipeline history cited acquisition of Halneuron in 4Q24; licensing of SP16 in 4Q25; licensing out of IMC-1/IMC-2 in 2Q26.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only an","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL6qJXyB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634210520","title":"Dogwood Therapeutics Inc  expected to post a loss of 26 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634210520","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634210520?lang=en_us&edition=fundamental","pubTime":"2026-05-12 22:08","pubTimestamp":1778594887,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Inc  expected to post a loss of26cents a share - Earnings Preview Dogwood Therapeutics Inc DWTX.OQ DWTX.O is expected to  show no change in quarterly revenue when it reports  resu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL8N41P25F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633142175","title":"Dogwood Therapeutics to report Q1 2026 financial results before market open","url":"https://stock-news.laohu8.com/highlight/detail?id=2633142175","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633142175?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:32","pubTimestamp":1778157178,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics schedules Q1 2026 financial results for Thursday, May 14, 2026, before U.S. market open.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL7tnpzq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2095319765.USD","SG9999014039.USD","SG9999014021.USD","BK4585","LU2210150020.SGD","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","BK4112","BK4139","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","IE00BKPKM429.USD","LU2210149790.SGD","DWTX","SG9999014013.SGD","BK4588","LU0314104364.USD","SG9999014005.SGD","IE00BN0W2V16.EUR","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":47,"code":"91000000","status":"200"}]}}